Sur8/Shoc2 promotes cell motility and metastasis through activation of Ras-PI3K signaling

Oncotarget

Volumn 6, Issue 32, 2015, Pages 33091-33105

  Kaduwal, Saluja ^a   Jeong, Woo Jeong ^a   Park, Jong Chan ^a   Lee, Kug Hwa ^a   Lee, Young Mi ^a,c   Jeon, Soung Hoo ^a,d   Lim, Yong beom ^a   Min, Do Sik ^a,b   Choi, Kang Yell ^a  

^a Yonsei University   (South Korea)

^b Pusan National University   (South Korea)

^c Hanmi Pharmaceutical Co Ltd   (South Korea)

^d Seoul National University College of Medicine   (South Korea)

Author keywords

Cell migration; Metastasis; PI3K; Ras; Sur8

Indexed keywords

EPIDERMAL GROWTH FACTOR; MATRIX METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; RAF PROTEIN; RAS PROTEIN; SCAFFOLD PROTEIN; SCAFFOLD PROTEIN SHOC2; SCAFFOLD PROTEIN SUR8; UNCLASSIFIED DRUG; SHOC2 PROTEIN, HUMAN; SIGNAL PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INVASION; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; ENZYME ACTIVATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LENTIVIRINAE; MALE; MELANOMA; MELANOMA CELL; METASTASIS; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; 3T3 CELL LINE; ANIMAL; CELL MOTION; EXPERIMENTAL MELANOMA; GENETICS; HEK293 CELL LINE; LUNG TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; SECONDARY; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CELL MOVEMENT; EPIDERMAL GROWTH FACTOR; HEK293 CELLS; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; NEOPLASM METASTASIS; NIH 3T3 CELLS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RAF KINASES; RAS PROTEINS; SIGNAL TRANSDUCTION;

EID: 84946067501     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.5173     Document Type: Article

References (48)

1. Giehl K. Oncogenic Ras in tumour progression and metastasis. Biol Chem. 2005; 386:193-205.
2. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nature Rev Cancer. 2007; 7:295-308.
3. Castellano E, Downward J. RAS interaction with PI3K: more than just another effector pathway. Genes Cancer. 2011; 2:261-274.
4. Choi C, Helfman DM. The Ras-ERK pathway modulates cytoskeleton organization, cell motility and lung metastasis signature genes in MDA-MB-231 LM2. Oncogene. 2014; 33:3668-3676.
5. Rajalingam K, Wunder C, Brinkmann V, Churin Y, Hekman M, Sievers C, Rapp UR, Rudel T. Prohibitin is required for Ras-induced Raf-MEK-ERK activation and epithelial cell migration. Nature Cell Biol. 2005; 7:837-843.
6. Cantley LC. The phosphoinositide 3-kinase pathway. Science. 2002; 296:1655-1657.
7. Rodriguez-Viciana P, Warne PH, Khwaja A, Marte BM, Pappin D, Das P, Waterfield MD, Ridley A, Downward J. Role of phosphoinositide 3-OH kinase in cell transformation and control of the actin cytoskeleton by Ras. Cell. 1997; 89:457-467.
8. Gupta S, Ramjaun AR, Haiko P, Wang Y, Warne PH, Nicke B, Nye E, Stamp G, Alitalo K, Downward J. Binding of ras to phosphoinositide 3-kinase p110alpha is required for ras-driven tumorigenesis in mice. Cell. 2007; 129:957-968.
9. Choi KY, Satterberg B, Lyons DM, Elion EA. Ste5 tethers multiple protein kinases in the MAP kinase cascade required for mating in Scerevisiae. Cell. 1994; 78:499-512.
10. Bhattacharyya RP, Remenyi A, Yeh BJ, Lim WA. Domains, motifs, and scaffolds: the role of modular interactions in the evolution and wiring of cell signaling circuits. Annu Rev Biochem. 2006; 75:655-680.
11. Good MC, Zalatan JG, Lim WA. Scaffold proteins: hubs for controlling the flow of cellular information. Science. 2011; 332:680-686.
12. Zeke A, Lukacs M, Lim WA, Remenyi A. Scaffolds: interaction platforms for cellular signalling circuits. Trends Cell Biol. 2009; 19:364-374.
13. Sieburth DS, Sun Q, Han M. SUR-8, a conserved Rasbinding protein with leucine-rich repeats, positively regulates Ras-mediated signaling in Celegans. Cell. 1998; 94:119-130.
14. Selfors LM, Schutzman JL, Borland CZ, Stern MJ. soc-2 encodes a leucine-rich repeat protein implicated in fibroblast growth factor receptor signaling. Proc Natl Acad Sci USA. 1998; 95:6903-6908.
15. Li W, Han M, Guan KL. The leucine-rich repeat protein SUR-8 enhances MAP kinase activation and forms a complex with Ras and Raf. Genes & development. 2000; 14:895-900.
16. Rodriguez-Viciana P, Oses-Prieto J, Burlingame A, Fried M, McCormick F. A phosphatase holoenzyme comprised of Shoc2/Sur8 and the catalytic subunit of PP1 functions as an M-Ras effector to modulate Raf activity. Molecular cell. 2006; 22:217-230.
17. Young LC, Hartig N, Munoz-Alegre M, Oses-Prieto JA, Durdu S, Bender S, Vijayakumar V, Vietri Rudan M, Gewinner C, Henderson S, Jathoul AP, Ghatrora R, Lythgoe MF, Burlingame AL, Rodriguez-Viciana P. An MRAS, SHOC2, and SCRIB complex coordinates ERK pathway activation with polarity and tumorigenic growth. Molecular cell. 2013; 52:679-692.
18. Ribeiro CM, Reece J, Putney JW Jr. Role of the cytoskeleton in calcium signaling in NIH 3T3 cells. An intact cytoskeleton is required for agonist-induced [Ca2+] i signaling, but not for capacitative calcium entry. J Biol Chem. 1997; 272:26555-26561.
19. Lauffenburger DA, Horwitz AF. Cell migration: a physically integrated molecular process. Cell. 1996; 84:359-369.
20. Mitchison TJ, Cramer LP. Actin-based cell motility and cell locomotion. Cell. 1996; 84:371-379.
21. Raftopoulou M, Hall A. Cell migration: Rho GTPases lead the way. Dev Biol. 2004; 265:23-32.
22. Brzeska H, Szczepanowska J, Matsumura F, Korn ED. Rac-induced increase of phosphorylation of myosin regulatory light chain in HeLa cells. Cell Motil Cytoskeleton. 2004; 58:186-199.
23. Ray RM, Vaidya RJ, Johnson LR. MEK/ERK regulates adherens junctions and migration through Rac1. Cell Motil Cytoskeleton. 2007; 64:143-156.
24. Scita G, Tenca P, Frittoli E, Tocchetti A, Innocenti M, Giardina G, Di Fiore PP. Signaling from Ras to Rac and beyond: not just a matter of GEFs. EMBO J. 2000; 19:2393-2398.
25. Park JH, Han HJ. Caveolin-1 plays important role in EGFinduced migration and proliferation of mouse embryonic stem cells: involvement of PI3K/Akt and ERK. Am J Physiol Cell Physiol. 2009; 297:C935-944.
26. Qiu Q, Yang M, Tsang BK, Gruslin A. EGF-induced trophoblast secretion of MMP-9 and TIMP-1 involves activation of both PI3K and MAPK signalling pathways. Reproduction. 2004; 128:355-363.
27. Page-McCaw A, Ewald AJ, Werb Z. Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol. 2007; 8:221-233.
28. Russo A, Ficili B, Candido S, Pezzino FM, Guarneri C, Biondi A, Travali S, McCubrey JA, Spandidos DA, Libra M. Emerging targeted therapies for melanoma treatment (review). Int J Oncol. 2014; 45:516-524.
29. Hart IR. The selection and characterization of an invasive variant of the B16 melanoma. Am J Pathol. 1979; 97:587-600.
30. Friedl P, Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nature Rev Cancer. 2003; 3:362-374.
31. Meng F, Wu G. The rejuvenated scenario of epithelial-mesenchymal transition (EMT) and cancer metastasis. Cancer Metastasis Rev. 2012; 31:455-467.
32. Normanno N, De Luca A, Bianco C, Strizzi L, Mancino M, Maiello MR, Carotenuto A, De Feo G, Caponigro F, Salomon DS. Epidermal growth factor receptor (EGFR) signaling in cancer. Gene. 2006; 366:2-16.
33. Sebastian S, Settleman J, Reshkin SJ, Azzariti A, Bellizzi A, Paradiso A. The complexity of targeting EGFR signalling in cancer: from expression to turnover. Biochimica et biophysica acta. 2006; 1766:120-139.
34. Sibilia M, Kroismayr R, Lichtenberger BM, Natarajan A, Hecking M, Holcmann M. The epidermal growth factor receptor: from development to tumorigenesis. Differentiation; research in biological diversity. 2007; 75:770-787.
35. Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989; 49:4682-4689.
36. Pylayeva-Gupta Y, Grabocka E, Bar-Sagi D. RAS oncogenes: weaving a tumorigenic web. Nature Rev Cancer. 2011; 11:761-774.
37. Takashima A, Faller DV. Targeting the RAS oncogene. Expert Opin Ther Targets. 2013; 17:507-531.
38. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S, Price TJ, Shepherd L, Au HJ, Langer C, Moore MJ, Zalcberg JR. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008; 359:1757-1765.
39. Lievre A, Bachet JB, Le Corre D, Boige V, Landi B, Emile JF, Cote JF, Tomasic G, Penna C, Ducreux M, Rougier P, Penault-Llorca F, Laurent-Puig P. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res. 2006; 66:3992-3995.
40. Park KS, Jeon SH, Kim SE, Bahk YY, Holmen SL, Williams BO, Chung KC, Surh YJ, Choi KY. APC inhibits ERK pathway activation and cellular proliferation induced by RAS. J Cell Sci. 2006; 119:819-827.
41. Lee DJ, Kang DH, Choi M, Choi YJ, Lee JY, Park JH, Park YJ, Lee KW, Kang SW. Peroxiredoxin-2 represses melanoma metastasis by increasing E-Cadherin/betaCatenin complexes in adherens junctions. Cancer research. 2013; 73:4744-4757.
42. Choi JM, Devkota S, Sung YH, Lee HW. EI24 regulates epithelial-to-mesenchymal transition and tumor progression by suppressing TRAF2-mediated NF-kappaB activity. Oncotarget. 2013; 4:2383-2396.
43. Jeong WJ, Yoon J, Park JC, Lee SH, Lee SH, Kaduwal S, Kim H, Yoon JB, Choi KY. Ras stabilization through aberrant activation of Wnt/beta-catenin signaling promotes intestinal tumorigenesis. Sci Signal. 2012; 5:ra30.
44. Moon BS, Kim HY, Kim MY, Yang DH, Lee JM, Cho KW, Jung HS, Choi KY. Sur8/Shoc2 involves both inhibition of differentiation and maintenance of self-renewal of neural progenitor cells via modulation of extracellular signalregulated kinase signaling. Stem Cells. 2011; 29:320-331.
45. Newcomb DC, Sajjan US, Nagarkar DR, Wang Q, Nanua S, Zhou Y, McHenry CL, Hennrick KT, Tsai WC, Bentley JK, Lukacs NW, Johnston SL, Hershenson MB. Human rhinovirus 1B exposure induces phosphatidylinositol 3-kinase-dependent airway inflammation in mice. Am J Respir Crit Care Med. 2008; 177:1111-1121.
46. Moissoglu K, Slepchenko BM, Meller N, Horwitz AF, Schwartz MA. In vivo dynamics of Rac-membrane interactions. Mol Biol Cell. 2006; 17:2770-2779.
47. Sander EE, ten Klooster JP, van Delft S, van der Kammen RA, Collard JG. Rac downregulates Rho activity: reciprocal balance between both GTPases determines cellular morphology and migratory behavior. J Cell Biol. 1999; 147:1009-1022.
48. Kim SE, Yoon JY, Jeong WJ, Jeon SH, Park Y, Yoon JB, Park YN, Kim H, Choi KY. H-Ras is degraded by Wnt/beta-catenin signaling via beta-TrCP-mediated polyubiquitylation. J Cell Sci. 2009; 122:842-848.